NCT06817720View on ClinicalTrials.gov

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 13, 2025

Primary Completion Date

March 7, 2027

Study Completion Date

March 7, 2027

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

olverembatinib

GIven by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Ascentage Pharma Group Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER